Where Am I?
Tag Cloud

Cross-Border E-Commerce: An Alternative Solution for Healthcare and Cosmetic Products? (Beijing)

BritCham / CBBC
Event type Seminar organised by British Chamber / China-Britain Business Council
Date Wednesday, June 3rd, 2015
Time 15:00-17:00
Open for All welcome
Cost Members 100 RMB Non-Members 300 RMB
Contacts steven.lynch@cbbc.org.cn; +86 (0)10 8525 1111 ext. 704
Venue The British Business Centre, Beijing
Organiser BritCham / CBBC
Address Room 1001, China Life Tower, 16 Chaoyangmenwai Dajie
北京市朝阳区朝阳门外大街16号中国人寿大厦1001室 英国商务中心
Do you like this article? Share it with your friends!  
Like! Tweet! Weibo Share on LinkedIn
If you deal with cosmetic products in China, you’ve probably been confronted by the ethical hurdle of animal testing. And if you’re selling portable medical devices, or supplying health supplements and foods, you’ve probably found yourself tied up in red tape. But does this mean no market access to China?
Not if there’s another solution. In this case the panacea is cross-border e-commerce, which offers new routes to market in the healthcare and life sciences industry, especially for healthcare and cosmetic products. The rise of the internet spells the “death of distance” – and a new lease of life for your business.
Join CBBC with speakers from the British Embassy, KJT and Sinopharm (国药集团), the biggest state-owned enterprise in the Chinese healthcare industry and one of the global Fortune 500, to discover how cross-border e-commerce provides an alternative solution to the traditional business model in your industry. 
Topics to be covered include:
  • Policy/regulatory changes 
  • Cosmetics
  • Medical devices
  • Health foods and supplements
An interpreter will be present at the event.
15:00 Registration
15:30 Welcome by Anna Zhao, CBBC Sector Lead for Healthcare & Life Sciences
15:35 Policy update with focus on animal testing: Karen Maddocks, First Secretary, British Embassy 
15:50 Cross-border e-commerce introduction: Mr YANG Jun, BD Director, KJT
16:15 Case study: Sinopharm Direct Sales in Shanghai Free Trade Zone: Madam ZHANG Yiyong, GM, Shanghai Direct Sales, Sinopharm Group
16:30 Q&A
17:00 Networking
Anna Zhao
China Business Advisor (Healthcare & Life Sciences), China-Britain Business Council
Anna worked for the British Embassy in Beijing for nine years, leading its healthcare and life sciences team across China to help UK businesses. She worked with established large corporates as well as SMEs new to China, and initiated and led UK-China government dialogues on market access issues. Anna used to be an anaesthetist and spent 10 years in medical practice in both China and the UK before moving into business. She holds an MBA in International Hospital Management.
Karen Maddocks
First Secretary and Head of Science and Innovation Network, British Embassy Beijing
Karen is First Secretary and Head of the Beijing Science and Innovation team, based in the British Embassy. Her role in Beijing is to shape the strategic focus of the Beijing team in line with UK and China priorities, to provide policy advice and to coordinate the delivery of projects which enable greater UK-China science collaboration and promote British research and innovation excellence and opportunities in China. She is leading the Embassy’s policy work with Chinese partners on animal welfare and ethics standards in the pharmaceuticals and cosmetics industries. Karen is a social scientist with an MSc in Global Development Management. She has worked for the Foreign and Commonwealth Office for 13 years, specialising in the Asia-Pacific region, including overseas postings in Vietnam, New Zealand and China.  
Yang Jun
Business Development Director, KJT
Yang Jun has worked for KJT since 2014 as BD Director. Before that, he worked for eBay HK from 2008 and Eastern Multimedia Group (TW) for cross-border business from 2012. Graduated from ESC Rennes with a degree in electronic engineering and has operated in cross-border e-commerce for more than 10 years.
China National Pharmaceutical Group Corporation (Sinopharm) 
China National Pharmaceutical Group Corporation (Sinopharm) is the largest Chinese medical and healthcare group directly managed by the State-owned Assets Supervision and Administration Commission of the State Council (SASAC), with the most complete industrial chain coverage and strongest comprehensive competence in China. Our core businesses include distribution, retail, scientific research and manufacture of healthcare related products and we own 11 wholly-owned or holding subsidiaries, and 6 listed companies: Sinopharm Group Co., Ltd., China National Medicines Co., Ltd., Sinopharm Accord Medicines Co., Ltd., Beijing Tiantan Biological Products Co., Ltd., Shanghai Shyndec Pharmaceutical Co., Ltd. and China Traditional Chinese Medicine Co. Ltd.. From 2003 to 2013, our annual average revenue growth was 31%, annual average gross profit growth was 42% and annual average total assets growth was 32%. In 2013, our sales revenue exceeded RMB 200 billion and we became the first Chinese pharmaceutical company to enter the Global Top 500.
Please contact:
Steven Lynch
+86 (0)10 8525 1111 ext. 704


please login first to get access to events registration!
Follow us